Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

1.41
Delayed Data
As of Nov 21
 +0.05 / +3.68%
Today’s Change
0.73
Today|||52-Week Range
1.78
+11.90%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$400.1M

Company Description

Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza, and Ebola virus. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Contact Information

Novavax, Inc.
20 Firstfield Road
Gaithersburg Maryland 20878
P:(240) 268-2000
Investor Relations:

Employees

Shareholders

Individual stakeholders6.89%
Mutual fund holders22.15%
Other institutional18.49%

Top Executives

Stanley C. ErckPresident, CEO, Chief Financial Officer & Director
Timothy Jon HahnSenior VP-Global Manufacturing Operations
Louis F. FriesChief Medical Officer & Senior Vice President
John A. HerrmannSecretary, Senior Vice President & General Counsel
Jill HoytVice President-Human Resources & Administration